Loading comparison data...
Medical Disclaimer: This site provides informational comparisons only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or pharmacist before making medication decisions.
Compare Natalizumab (Tysabri) and Ocrelizumab (Ocrevus) — clinical data, side effects, and patient experiences.
Tysabri · Integrin Inhibitor
How it works
Humanized monoclonal antibody against alpha-4 integrin that blocks leukocyte migration across the blood-brain barrier.
Approved for
Ocrevus · Anti-CD20 Monoclonal Antibody
How it works
Humanized anti-CD20 monoclonal antibody that depletes B cells via antibody-dependent cellular cytolysis and complement-mediated lysis.
Approved for
Estimated frequency (%) based on clinical trial data
No specific warnings
Based on 8 Reddit discussions
Natalizumab
63%
positive
8 threads
Ocrelizumab
0%
positive
0 threads
% of discussions mentioning each side effect
8 Reddit threads analysed for Natalizumab
Overall Sentiment
Slightly positive
Comparison Threads
0
Avg Post Score
41 upvotes
Most discussed side effects in community
Study this article is based on: https://jamanetwork.com/journals/jama/article-abstract/2720726 Source: https://www.zmescience.com/science/multiple-sclerosis-treatment-82534524/ The worst of multiple sclerosis can be avoided or delayed with early treatment LAST UPDATED ON JANUARY 19TH, 2019 AT 6:21 P
# [Results of 2b/3 clinical trial for Dupuytren’s Disease’ Being Presented Wednesday, December 1, 2021, at 3pm EST](https://ir.180lifesciences.com/news-events/press-releases/detail/49/180-life-sciences-corp-co-founder-prof-jagdeep-nanchahal) Top line data for Dupuytren's disease phase 2b/3 clinical
Hi everyone. I have recently had a PML scare, got the all clear this morning (yay!), and thought it may be of interest to people here who have worries about PML. I am based in the UK, and the neuro services for the county are provided by a different hospital Trust. I was diagnosed back in 2011. I tr
edit: article below says it's rare. far below there are actual numbers of incidents reported and more details. ​ FDA direct link: [https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm626264.htm](https://www.fda.gov/Safety/MedWatch/SafetyInformat
# [Results of 2b/3 clinical trial for Dupuytren’s Disease’ Being Presented Wednesday, December 1, 2021, at 3pm EST](https://ir.180lifesciences.com/news-events/press-releases/detail/49/180-life-sciences-corp-co-founder-prof-jagdeep-nanchahal) Top line data for Dupuytren's disease phase 2b/3 clinical
Hi all, First time poster here! Unfortunately I, (27/f), have joined the MS club, not a club I wanted to join, but I just wanted to say how grateful I am for this community. Makes me not feel so alone. I first got diagnosed after having optic neuritis in my left eye a month ago, my sight is slowly
ATNF (180 Life Sciences) Super low float MASSIVE potential with a ALL STAR DREAM TEAM MANAGEMENT with a proven track record second to none. 40X or more return very likely. Please read in full: ATNF (180 Life sciences) Super low floater massive potential under the radar Gem with a "DREAM TEAM All
*(A bit long but worth it)* **People with multiple sclerosis (MS) have significantly more T-cells equipped with receptors that specifically recognize the Epstein-Barr virus (EBV) than do healthy individuals, a study revealed.** Notably, no such differences were detected for T-cells with receptors sp
Community discussions are sourced from public Reddit threads. Content reflects individual opinions and is not medical advice.
No community discussions found for Ocrelizumab yet.
Natalizumab is a Integrin Inhibitor, while Ocrelizumab belongs to the Anti-CD20 Monoclonal Antibody class. This means they work through different pharmacological mechanisms, which may influence both efficacy and side effect profiles. Natalizumab is administered via Oral, whereas Ocrelizumab uses Intravenous. Route of administration can affect onset of action and patient adherence.
Both medications are approved for Relapsing Multiple Sclerosis. When two drugs treat the same condition, the choice between them often depends on the patient's medical history, other medications, tolerability, and prescriber preference.
Ocrelizumab carries 3 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..
This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.